Business Wire

TX-TYAN

15.11.2022 16:01:37 CET | Business Wire | Press release

Share
TYAN Introduces HPC, Cloud and Storage Server Platforms Featuring 4th Gen AMD EPYC™ Processors at SC22

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings the latest HPC, cloud and storage platforms powered by AMD EPYC™ 9004 Series processors for the next generation server architecture and energy efficiency at SC22, Booth #2000 in the Kay Bailey Hutchison Convention Center Dallas through November 17th.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005027/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TYAN Server Platforms Powered by AMD EPYC 9004 Series Processors are Designed for the Next Generation Server Architecture (Photo: Business Wire)

“Facing the post-COVID economy world, data centers are required to build on more environmentally friendly, secure and flexible features to respond to the growing of teleworking, video streaming, IoT and 5G,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation’s Server Infrastructure BU. “TYAN’s new server platforms, powered by 4th Gen AMD EPYC processors, efficiently enable data centers by doing more tasks with the same number of servers.”

"4th Gen AMD EPYC processors are the world's highest performance server CPUs that deliver leadership energy efficiency as well as low total cost of ownership across workloads and industries. By adopting 4th Gen AMD EPYC processors, enterprises can optimize their data center footprint to do more with less, accelerating their core business while helping address their sustainability goals," said Ram Peddibhotla, corporate vice president, EPYC product management, AMD.

Optimized for the most demanding workloads in today’s HPC data centers

Leveraging 4th Gen AMD EPYC processors’ support for high performance DDR5 memory and fast PCIe® Gen 5 I/O, TYAN’s HPC platforms enable the high performance demands of today’s AI and machine learning applications. The Tomcat HX S8050 server motherboard provides eight DDR5 DIMM slots, five PCIe 5.0 x16 slots, four MCIO connectors, two NVMe M.2 slots, two 10GbE and two GbE onboard Ethernet ports in CEB (12" x 10.5") form factor.

The Transport HX FT65T-B8050 is a rack-convertible pedestal server platform featuring a single AMD EYPC 9004 Series processor, eight DDR5 DIMM slots, eight 3.5” SATA and two 2.5” NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8050 supports up to two double-wide PCIe 5.0 x16 professional GPUs along with two additional high-speed networking adapters for parallel clustered workloads.

Data cache and high-density with front I/O servers to power the cloud

TYAN’s cloud platforms benefit from the innovations of AMD EPYC 9004 Series processors and are designed for cloud and data analytics applications that help move data faster. The Transport CX GC68A-B8056 is a cost-optimized single-socket server platform featuring 24 DDR5 DIMM slots, a pair of PCIe 5.0 x16 expansion slots, one OCP 3.0 LAN mezzanine slot and two 10GbE onboard Ethernet ports in 1U configuration. The GC68A-B8056 accommodates twelve 2.5” tool-less drive bays supporting NVMe U.2 devices for applications which require outstanding compute cores as well as high performance storage I/Os.

The Transport CX TD76-B8058 is a 2U multi-node server platform with four front-service nodes. Each node supports one AMD EPYC 9004 Series processor, 16 DDR5 DIMM slots, four hot-swap E1.S drive bays, two internal NVMe M.2 slots, one standard PCIe 5.0 x16 expansion, and one OCP 3.0 LAN mezzanine slot. The platform is suited for high-density data center deployment, front-end web servers, and variety of scale-out applications with large numbers of nodes.

Hybrid and all-flash storage server to maximize application performance

TYAN’s storage platforms are designed to deliver massive data I/O between memory and storage devices for cloud applications. TYAN's Transport SX TS70-B8056 and Transport SX TS70A-B8056 are 2U single-socket storage servers with support for 24 DDR5 DIMM slots, three PCIe 5.0 and one OCP 3.0 LAN mezzanine slots. The TS70-B8056 accommodates twelve front 3.5” drive bays with up to four NVMe U.2 support, and two rear 2.5” NVMe U.2 hot-swap, tool-less drive bays for boot drive deployment; the TS70A-B8056 offers 26 2.5” NVMe U.2 hot-swap, tool-less drive bays for high IOPs requirement in high-performance data streaming applications.

Supporting Resources:

Please watch this video about TYAN 4th Gen AMD EPYC processor-based servers designed for modern data centers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005027/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye